Journal: Clinical and experimental pharmacology & physiology

Article Title: Drug resistance and cancer stem cells: the shared but distinct roles of hypoxia-inducible factors HIF1? and HIF2?.

PMID/MRN: 27809360

Publication Date: 2016-Nov-03

Abstract:

Chemotherapy resistance is a major contributor to poor treatment responses and tumour relapse due to the action of cancer stem cells (CSCs). Mounting evidence suggests these CSCs are reliant on low oxygen conditions and hypoxia-inducible factors 1? and 2? (HIF1? and HIF2?) to maintain their stem cell features. Further research in the last decade has begun to clarify the functional differences between the two HIF? subtypes; here, we review and discuss these differences in relation to CSC drug resistance. Both HIF?s contribute to CSC survival but play different roles - with HIF1? more responsible for survival functions and HIF2? more specific for stemness traits such as self-renewal - and are sensitive to different degrees of hypoxia. Failure to account for physiologically relevant oxygen concentrations in many studies may influence the current understanding of the roles of HIF?s. We also discuss how hypoxia and HIF?s contribute to CSC drug resistance via promotion of ABC drug transporters BCRP, MDR1, and MRP1 and through maintenance of quiescence. Additionally, we explore the PI3K/AKT cell survival pathway that may support refractory cancer by promoting CSCs and activating both HIF1? and HIF2?. Accordingly, HIF1? and HIF2? inhibition, potentially via PI3K/AKT inhibitors, could reduce chemotherapy resistance and prevent cancer relapse. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.